William M Gallagher

List of Publications by Year
in descending order

231 papers	17,511 citations	18482 **62** h-index	15732 **125** g-index
240 all docs	240 docs citations	240 times ranked	29395 citing authors

#	ARTICLE	IF	CITATIONS
1	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	9.4	1,486
2	Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, 2009, 85, 1053-1074.	2.5	1,029
3	A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13556-13561.	7.1	990
4	Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. Cancer Research, 2013, 73, 1128-1141.	0.9	797
5	In Vitro Demonstration of the Heavy-Atom Effect for Photodynamic Therapy. Journal of the American Chemical Society, 2004, 126, 10619-10631.	13.7	768
6	Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis, 2013, 34, 2300-2308.	2.8	359
7	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research, 2011, 17, 6083-6096.	7.0	330
8	Synthesis of BF2chelates of tetraarylazadipyrromethenes and evidence for their photodynamic therapeutic behaviour. Chemical Communications, 2002, , 1862-1863.	4.1	324
9	Supramolecular Photonic Therapeutic Agents. Journal of the American Chemical Society, 2005, 127, 16360-16361.	13.7	323
10	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
11	Effect of Surface Wettability and Topography on the Adhesion of Osteosarcoma Cells on Plasma-modified Polystyrene. Journal of Biomaterials Applications, 2011, 26, 327-347.	2.4	314
12	Fibulins: physiological and disease perspectives. EMBO Reports, 2003, 4, 1127-1131.	4.5	288
13	Survivin: A promising tumor biomarker. Cancer Letters, 2007, 249, 49-60.	7.2	229
14	hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 1997, 15, 45-52.	5.9	226
15	miRNA Dysregulation in Breast Cancer. Cancer Research, 2013, 73, 6554-6562.	0.9	217
16	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	3.7	209
17	Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction. Biomaterials, 2006, 27, 3096-3108.	11.4	208
18	miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget, 2015, 6, 32774-32789.	1.8	203

#	Article	IF	Citations
19	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death and Differentiation, 2014, 21, 1250-1261.	11.2	195
20	A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment. Cancer Research, 2012, 72, 66-75.	0.9	189
21	p53 as a target for the treatment of cancer. Cancer Treatment Reviews, 2014, 40, 1153-1160.	7.7	187
22	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nature Reviews Cancer, 2010, 10, 605-617.	28.4	181
23	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Molecular Cancer, 2011, 10, 126.	19.2	170
24	Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time. Nature Communications, 2016, 7, 10855.	12.8	164
25	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nature Communications, 2011, 2, 555.	12.8	152
26	Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. Oncogene, 2018, 37, 2137-2149.	5.9	150
27	The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility. Biomaterials, 2010, 31, 8188-8197.	11.4	149
28	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	3.3	143
29	Bioluminescent imaging: a critical tool in preâ€clinical oncology research. Journal of Pathology, 2010, 220, 317-327.	4.5	139
30	Fibulins and cancer: friend or foe?. Trends in Molecular Medicine, 2005, 11, 336-340.	6.7	134
31	An Intact Canonical NF-Î°B Pathway Is Required for Inflammatory Gene Expression in Response to Hypoxia. Journal of Immunology, 2011, 186, 1091-1096.	0.8	134
32	Increased claudinâ€4 expression is associated with poor prognosis and high tumour grade in breast cancer. International Journal of Cancer, 2009, 124, 2088-2097.	5.1	128
33	Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers. Cancer Research, 2012, 72, 2428-2439.	0.9	124
34	BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome. Breast Cancer Research, 2013, 15, R52.	5.0	124
35	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clinical Cancer Research, 2006, 12, 6421-6431.	7.0	123
36	Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. Molecular Oncology, 2014, 8, 783-798.	4.6	122

#	Article	IF	Citations
37	JAMâ€A expression positively correlates with poor prognosis in breast cancer patients. International Journal of Cancer, 2009, 125, 1343-1351.	5.1	115
38	Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Research, 2008, 10, R89.	5.0	113
39	Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis, 2005, 26, 1856-1867.	2.8	108
40	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nature Medicine, 2015, 21, 741-750.	30.7	107
41	The Role of Exosomes in Breast Cancer. Clinical Chemistry, 2015, 61, 1457-1465.	3.2	105
42	Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Review of Molecular Diagnostics, 2008, 8, 707-725.	3.1	104
43	Performance of Novel Kidney Biomarkers in Preclinical Toxicity Studies. Toxicological Sciences, 2010, 116, 8-22.	3.1	101
44	A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia. British Journal of Cancer, 2005, 92, 1702-1710.	6.4	100
45	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. International Journal of Cancer, 2007, 120, 1434-1443.	5.1	98
46	Epigenetics of malignant melanoma. Seminars in Cancer Biology, 2018, 51, 80-88.	9.6	95
47	Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Journal of Organometallic Chemistry, 2004, 689, 2242-2249.	1.8	91
48	The Hydroxylase Inhibitor Dimethyloxallyl Glycine Attenuates Endotoxic Shock Via Alternative Activation of Macrophages and IL-10 Production by B1 Cells. Shock, 2011, 36, 295-302.	2.1	90
49	Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. , 2004, 102, 1-15.		88
50	Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer. Cellular and Molecular Life Sciences, 2007, 64, 3159-3184.	5.4	86
51	Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. British Journal of Cancer, 2009, 101, 1565-1573.	6.4	86
52	MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics, 2013, 14, 338.	2.6	84
53	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clinical Cancer Research, 2008, 14, 2681-2689.	7.0	83
54	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. European Journal of Cancer, 2009, 45, 1510-1517.	2.8	79

#	Article	IF	Citations
55	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 3834-3845.	0.9	79
56	Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?. International Journal of Cancer, 2017, 140, 234-246.	5.1	79
57	Interaction of soft condensed materials with living cells: Phenotype/transcriptome correlations for the hydrophobic effect. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6331-6336.	7.1	78
58	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential *In Vitro*. Clinical Cancer Research, 2012, 18, 6702-6713.	7.0	75
59	Elevated expression and altered processing of fibulin-1 protein in human breast cancer. British Journal of Cancer, 2003, 88, 871-878.	6.4	68
60	Heteroaryl substitutedansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Applied Organometallic Chemistry, 2005, 19, 293-300.	3.5	68
61	Identification of cell surface-specific markers to target human nucleus pulposus cells: Expression of carbonic anhydrase XII varies with age and degeneration. Arthritis and Rheumatism, 2011, 63, 3876-3886.	6.7	68
62	Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimitotic agent to vascular smooth muscle cells. Cardiovascular Pathology, 2003, 12, 105-110.	1.6	65
63	Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy. Annals of Surgery, 2007, 245, 259-266.	4.2	65
64	The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. Drug Discovery Today, 2011, 16, 219-228.	6.4	65
65	Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. BMC Cancer, 2013, 13, 175.	2.6	64
66	Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Letters, 2001, 489, 59-66.	2.8	62
67	Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. BMC Medicine, 2017, 15, 101.	5.5	62
68	Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis, 2004, 25, 1599-1609.	2.8	61
69	Molecular basis of cell‐biomaterial interaction: Insights gained from transcriptomic and proteomic studies. Biomaterials, 2006, 27, 5871-5882.	11.4	61
70	Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes. Circulation: Heart Failure, 2019, 12, e005765.	3.9	58
71	MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene, 1999, 18, 3608-3616.	5.9	56
72	Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. European Respiratory Journal, 2015, 46, 1762-1772.	6.7	56

#	Article	IF	Citations
73	Protein Tyrosine Phosphatases, New Targets for Cancer Therapy. Current Cancer Drug Targets, 2006, 6, 519-532.	1.6	55
74	The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate. Biomaterials, 2013, 34, 2710-2718.	11.4	55
75	Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. Journal of Inorganic Biochemistry, 2004, 98, 1987-1994.	3.5	54
76	The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development. Frontiers in Oncology, 2021, 11, 626349.	2.8	54
77	Peroxiredoxin-1 protects estrogen receptor Î± from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Research, 2014, 16, R79.	5.0	52
78	Serum Proteomic Profiling Reveals That Pretreatment Complement Protein Levels are Predictive of Esophageal Cancer Patient Response to Neoadjuvant Chemoradiation. Annals of Surgery, 2011, 254, 809-817.	4.2	51
79	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. Cancer Research, 2020, 80, 2983-2995.	0.9	51
80	Applications of SELDIâ€MS technology in oncology. Journal of Cellular and Molecular Medicine, 2008, 12, 1535-1547.	3.6	50
81	Clinical Decision Support Systems in Breast Cancer: A Systematic Review. Cancers, 2020, 12, 369.	3.7	50
82	The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. BMC Cancer, 2011, 11, 405.	2.6	48
83	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Letters, 2018, 414, 99-106.	7.2	48
84	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opinion on Biological Therapy, 2005, 5, 1069-1083.	3.1	46
85	Correlation of the Adhesive Properties of Cells to N-Isopropylacrylamide/N-tert-Butylacrylamide Copolymer Surfaces with Changes in Surface Structure Using Contact Angle Measurements, Molecular Simulations, and Raman Spectroscopy. Chemistry of Materials, 2005, 17, 3889-3898.	6.7	46
86	Low pH induces co-ordinate regulation of gene expression in oesophageal cells. Carcinogenesis, 2006, 27, 319-327.	2.8	46
87	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discovery Today, 2010, 15, 102-114.	6.4	45
88	Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Research, 2010, 20, 392-400.	1.2	44
89	Colitis susceptibility in mice with reactive oxygen species deficiency is mediated by mucus barrier and immune defense defects. Mucosal Immunology, 2019, 12, 1316-1326.	6.0	44
90	Formalinâ€fixed paraffinâ€embedded clinical tissues show spurious copy number changes in arrayâ€CGH profiles. Clinical Genetics, 2007, 72, 441-447.	2.0	43

#	Article	IF	Citations
91	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget, 2017, 8, 42949-42961.	1.8	42
92	Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investigational New Drugs, 2011, 29, 752-759.	2.6	41
93	Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2016, 4, 103.	3.7	41
94	The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. Journal of Biological Chemistry, 2017, 292, 3543-3551.	3.4	41
95	A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. Polyhedron, 2005, 24, 1250-1255.	2.2	40
96	Heteroaryl substituted titanocenes as potential anti-cancer drugs. Journal of Inorganic Biochemistry, 2006, 100, 1479-1486.	3.5	40
97	Vitamin D receptor as a target for breast cancer therapy. Endocrine-Related Cancer, 2017, 24, 181-195.	3.1	40
98	Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer, 2010, 10, 125.	2.6	39
99	High-Throughput Proteomics Detection of Novel Splice Isoforms in Human Platelets. PLoS ONE, 2009, 4, e5001.	2.5	38
100	Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer, 2010, 10, 639.	2.6	38
101	Functionalized Scaffold-mediated Interleukin 10 Gene Delivery Significantly Improves Survival Rates of Stem Cells In Vivo. Molecular Therapy, 2011, 19, 969-978.	8.2	38
102	Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: An initial report from the PredTox group. Experimental and Toxicologic Pathology, 2008, 60, 235-245.	2.1	37
103	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. Angiogenesis, 2011, 14, 457-466.	7.2	37
104	Mechanism of cell death mediated by a BF_2‑chelated tetraaryl‑azadipyrromethene photodynamic therapeutic: Dissection of the apoptotic pathway *in vitro* and *in vivo*. International Journal of Cancer, 2012, 130, 705-715.	5.1	36
105	microRNAs: a new class of breast cancer biomarkers. Expert Review of Molecular Diagnostics, 2014, 14, 347-363.	3.1	36
106	SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Research, 2010, 20, 468-478.	1.2	35
107	Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Research, 2010, 20, 392-400.	1.2	35
108	Effects of HER Family‑targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Clinical Cancer Research, 2021, 27, 807-818.	7.0	34

#	ARTICLE	IF	CITATIONS
109	Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicology Letters, 2010, 196, 1-11.	0.8	33
110	RGD conjugated cell uptake off to on responsive NIR-AZA fluorophores: applications toward intraoperative fluorescence guided surgery. Chemical Science, 2019, 10, 6944-6956.	7.4	33
111	The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochemical Society Transactions, 2011, 39, 663-668.	3.4	32
112	Development of a Pharmaceutical Hepatotoxicity Biomarker Panel Using a Discovery to Targeted Proteomics Approach. Molecular and Cellular Proteomics, 2012, 11, 394-410.	3.8	32
113	Novel â€œplum puddingâ€•gels as potential drug-eluting stent coatings: Controlled release of fluvastatin. Journal of Biomedical Materials Research - Part A, 2006, 79A, 923-933.	4.0	31
114	PKCÎ¶ regulates cell polarisation and proliferation restriction during mammary acinus formation. Journal of Cell Science, 2010, 123, 3316-3328.	2.0	31
115	Identification of Î²2â€•microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics - Clinical Applications, 2011, 5, 422-431.	1.6	31
116	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Modern Pathology, 2011, 24, 708-719.	5.5	31
117	Epidemiologic Design and Analysis for Proteomic Studies: A Primer on -Omic Technologies. American Journal of Epidemiology, 2015, 181, 635-647.	3.4	30
118	TGF-Î²1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascular Pharmacology, 2006, 44, 469-475.	2.1	29
119	Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Breast Cancer Research, 2017, 19, 87.	5.0	29
120	OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Molecular Cancer, 2014, 13, 241.	19.2	27
121	Standardization of Models and Methods Used to Assess Nanoparticles in Cardiovascular Applications. Small, 2011, 7, 705-717.	10.0	26
122	A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate. PLoS ONE, 2017, 12, e0169964.	2.5	26
123	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. Journal of Personalized Medicine, 2022, 12, 72.	2.5	26
124	Examination of cellâ€"hostâ€"biomaterial interactions via high-throughput technologies: A re-appraisal. Biomaterials, 2010, 31, 6667-6674.	11.4	25
125	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. Cancer Research, 2010, 70, 7776-7787.	0.9	25
126	Sequence Tagging Reveals Unexpected Modifications in Toxicoproteomics. Chemical Research in Toxicology, 2011, 24, 204-216.	3.3	25

#	Article	IF	Citations
127	Omic profiling for drug safety assessment: current trends and public–private partnerships. Drug Discovery Today, 2009, 14, 337-342.	6.4	24
128	Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro. Breast Cancer Research, 2010, 12, R59.	5.0	24
129	Use of proteomics for the discovery of early markers of drug toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 689-704.	3.3	23
130	Truncated HER2: implications for HER2-targeted therapeutics. Drug Discovery Today, 2011, 16, 810-816.	6.4	23
131	Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS ONE, 2015, 10, e0133449.	2.5	23
132	Prognostic and predictive biomarkers in melanoma: an update. Expert Review of Molecular Diagnostics, 2016, 16, 223-237.	3.1	23
133	Novel Method to Prepare Morphologically Rich Polymeric Surfaces for Biomedical Applications via Phase Separation and Arrest of Microgel Particles. Journal of Physical Chemistry B, 2006, 110, 14581-14589.	2.6	22
134	Selective Expression of Syntaxin-7 Protein in Benign Melanocytes and Malignant Melanoma. Journal of Proteome Research, 2009, 8, 1639-1646.	3.7	22
135	Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Research, 2011, 13, R12.	5.0	22
136	BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer. Oncotarget, 2018, 9, 15673-15690.	1.8	22
137	Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma. British Journal of Cancer, 2011, 105, 565-574.	6.4	21
138	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer, 2018, 18, 965.	2.6	21
139	Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell and Melanoma Research, 2010, 23, 542-553.	3.3	20
140	A Texture Based Pattern Recognition Approach to Distinguish Melanoma from Non-Melanoma Cells in Histopathological Tissue Microarray Sections. PLoS ONE, 2013, 8, e62070.	2.5	20
141	Investigation of molecular alterations of <i><scp>AKT</scp>‐3</i> in triple‐negative breast cancer. Histopathology, 2014, 64, 660-670.	2.9	20
142	PEGylated BF2-Azadipyrromethene (NIR-AZA) fluorophores, for intraoperative imaging. European Journal of Medicinal Chemistry, 2019, 161, 343-353.	5.5	19
143	High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. Cancers, 2020, 12, 2950.	3.7	19
144	Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. Journal of Clinical Pathology, 2021, 74, 429-434.	2.0	19

#	Article	IF	Citations
145	Identification of transcription factors associated with castration‐resistance: Is the serum responsive factor a potential therapeutic target?. Prostate, 2013, 73, 743-753.	2.3	18
146	Circulating MicroRNAs in Cancer. Methods in Molecular Biology, 2017, 1509, 123-139.	0.9	18
147	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. Clinical Cancer Research, 2019, 25, 7139-7150.	7.0	18
148	A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ERα in Breast Cancer. Cancer Research, 2020, 80, 5076-5088.	0.9	18
149	Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells. Antioxidants, 2020, 9, 320.	5.1	18
150	Prognostic ability of a panel of immunohistochemistry markers â€“ retailoring of an 'old solution'. Breast Cancer Research, 2008, 10, 102.	5.0	17
151	Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Scientific Reports, 2016, 6, 34523.	3.3	17
152	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. Clinical Cancer Research, 2019, 25, 6598-6605.	7.0	17
153	Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics and Proteomics, 2007, 4, 121-34.	2.0	17
154	Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell‐Cell Interactions That Predict Immunotherapy Response. Cancer Research, 2022, 82, 3275-3290.	0.9	17
155	High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of Interferon Gamma and Interleukin-10 post Myocardial Infarction. Clinical Immunology, 2009, 133, 251-256.	3.2	16
156	Surface‐induced cell signaling events control actin rearrangements and motility. Journal of Biomedical Materials Research - Part A, 2010, 93A, 493-504.	4.0	16
157	Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: A multi‐site, multi‐compound study. Proteomics, 2010, 10, 1592-1608.	2.2	16
158	De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage Iâ€“III breast cancer. British Journal of Cancer, 2016, 115, 592-598.	6.4	16
159	ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling. Oncogene, 2021, 40, 6235-6247.	5.9	16
160	The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides. Journal of Biotechnology, 2015, 204, 7-12.	3.8	15
161	Bringing Greater Accuracy to Europeâ€™s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine Hub, 2020, 5, 1-42.	1.2	15
162	Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. European Journal of Gastroenterology and Hepatology, 2011, 23, 177-183.	1.6	14

#	Article	IF	Citations
163	The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. Prostate, 2014, 74, 306-313.	2.3	14
164	PDLIM2 Is a Marker of Adhesion and Î²-Catenin Activity in Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 2619-2633.	0.9	14
165	Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients. Cancers, 2020, 12, 1133.	3.7	14
166	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. Clinical Epigenetics, 2021, 13, 168.	4.1	14
167	The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line. BMC Bioinformatics, 2006, 7, 256.	2.6	13
168	High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Research, 2015, 25, 189-199.	1.2	13
169	Commercialized biomarkers: new horizons in prostate cancer diagnostics. Expert Review of Molecular Diagnostics, 2015, 15, 491-503.	3.1	13
170	Evaluating liquid biopsies for methylomic profiling of prostate cancer. Epigenetics, 2020, 15, 715-727.	2.7	13
171	Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Oncotarget, 2018, 9, 6188-6200.	1.8	13
172	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	1.8	13
173	Proteomic analysis of factors released from p21-overexpressing tumour cells. Proteomics, 2006, 6, 3739-3753.	2.2	12
174	Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph nodeâ€negative breast cancer patients. FEBS Journal, 2015, 282, 3455-3473.	4.7	12
175	The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer. Oncotarget, 2016, 7, 75518-75525.	1.8	12
176	Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. Oncotarget, 2017, 8, 48126-48137.	1.8	12
177	A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. Breast Cancer Research, 2014, 16, 467.	5.0	11
178	RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2â€"Positive Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw111.	6.3	11
179	Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties. Nanotechnology, 2016, 27, 305603.	2.6	11
180	Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation. Cancer Research, 2017, 77, 2186-2190.	0.9	11

#	Article	IF	Citations
181	Frequency, impact and a preclinical study of novel *ERBB* gene family mutations in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877829.	3.2	11
182	An EPR Strategy for Bio-responsive Fluorescence Guided Surgery with Simulation of the Benefit for Imaging. Theranostics, 2020, 10, 3064-3082.	10.0	11
183	Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection. Analyst, The, 2021, 146, 4195-4211.	3.5	11
184	DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 289-304.	0.3	10
185	Identification and functional validation of therapeutic targets for malignant melanoma. Critical Reviews in Oncology/Hematology, 2009, 72, 194-214.	4.4	10
186	The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer. Oncogene, 2012, 31, 3483-3494.	5.9	10
187	Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986423.	3.2	10
188	Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study. Clinical Cancer Research, 2020, 26, 623-631.	7.0	10
189	Association of circulating short chain fatty acid levels with colorectal adenomas and colorectal cancer. Clinical Nutrition ESPEN, 2021, 46, 297-304.	1.2	10
190	Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. Expert Review of Proteomics, 2012, 9, 415-423.	3.0	9
191	Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. Journal of Molecular Medicine, 2018, 96, 1025-1037.	3.9	9
192	Breast cancer proteomics: clinical perspectives. Expert Opinion on Biological Therapy, 2007, 7, 209-219.	3.1	8
193	Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. Proteomics - Clinical Applications, 2008, 2, 1338-1348.	1.6	8
194	Role of serum response factor expression in prostate cancer biochemical recurrence. Prostate, 2018, 78, 724-730.	2.3	8
195	Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models. Cancers, 2020, 12, 2978.	3.7	8
196	Tissue Microarrays and Digital Image Analysis. Methods in Molecular Biology, 2011, 691, 97-112.	0.9	8
197	Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 2022, 26, 155-169.	3.4	8
198	Prioritization of Candidate Protein Biomarkers from an *In Vitro* Model System of Breast Tumor Progression Toward Clinical Verification. Journal of Proteome Research, 2010, 9, 1450-1459.	3.7	7

#	Article	IF	Citations
199	Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC Cancer, 2012, 12, 209.	2.6	7
200	Relationship between serum response factor and androgen receptor in prostate cancer. Prostate, 2015, 75, 1704-1717.	2.3	7
201	Plant-derived cannabinoids as anticancer agents. Trends in Cancer, 2022, 8, 350-357.	7.4	7
202	Advances in tissue-based imaging: impact on oncology research and clinical practice. Expert Review of Molecular Diagnostics, 2020, 20, 1027-1037.	3.1	5
203	<scp>PRR11</scp> unveiled as a top candidate biomarker within the <scp>RBM3</scp>â€regulated transcriptome in pancreatic cancer. Journal of Pathology: Clinical Research, 2022, 8, 65-77.	3.0	5
204	1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours. Oncotarget, 2019, 10, 3725-3744.	1.8	5
205	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
206	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. Expert Review of Molecular Diagnostics, 2016, 16, 541-551.	3.1	4
207	Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology. Methods in Molecular Biology, 2017, 1501, 311-325.	0.9	4
208	Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer. Cancers, 2020, 12, 3540.	3.7	4
209	Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland. Cancers, 2020, 12, 1921.	3.7	4
210	The Molecular Effects of a High Fat Diet on Endometrial Tumour Biology. Life, 2020, 10, 188.	2.4	4
211	Functional interrogation of breast cancer: from models to drugs. Expert Opinion on Drug Discovery, 2006, 1, 569-584.	5.0	3
212	Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Preâ€Clinical Detection of Offâ€Target Toxicities Associated with Sunitinib Malate. Proteomics - Clinical Applications, 2019, 13, e1800159.	1.6	3
213	Differential Proteomics Incorporating iTRAQ Labeling and Multi-dimensional Separations. Methods in Molecular Biology, 2011, 691, 369-383.	0.9	3
214	Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity. BMC Cancer, 2022, 22, 131.	2.6	3
215	DNA microarray-based transcriptomic profiling of an isogenic cell culture model of breast tumour cell invasion. Anticancer Research, 2007, 27, 1353-9.	1.1	3
216	Prognostic value of the 6-gene OncoMasTR test in hormone receptorâ€"positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. European Journal of Cancer, 2021, 152, 78-89.	2.8	2

#	Article	IF	Citations
217	Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.. Journal of Clinical Oncology, 2019, 37, 535-535.	1.6	2
218	Structural basis of p21H-ras molecular switch inhibition by a neutralizing antibody. Journal of Molecular Graphics, 1996, 14, 42-50.	1.1	1
219	Selected highlights of the Third Annual Biomarkers Congress: from discovery to validation in the drug development arena. Expert Opinion on Medical Diagnostics, 2008, 2, 1091-1094.	1.6	1
220	Focus on Cancer Proteomics 12'13. Proteomics, 2012, 12, 2065-2066.	2.2	1
221	Postmortem Examination of an Aggressive Case of Medullary Thyroid Carcinoma Characterized by Catastrophic Genomic Abnormalities. JCO Precision Oncology, 2017, 1, 1-7.	3.0	1
222	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptorâ€"Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. Clinical Cancer Research, 2021, 27, 5931-5938.	7.0	1
223	Focus on Cancer Proteomics: From Discovery towards Validation. Proteomics - Clinical Applications, 2010, 4, 577-578.	1.6	0
224	Fibulins and Their Role in the ECM. , 2011, , 159-174.		0
225	A Machine Learning System for Identifying Hypertrophy in Histopathology Images. Lecture Notes in Computer Science, 2010, , 72-81.	1.3	0
226	PKCÎ¶ regulates cell polarisation and proliferation restriction during mammary acinus formation. Development (Cambridge), 2010, 137, e2007-e2007.	2.5	0
227	Fibulins. , 2011, , 1403-1406.		0
228	Fibulins. , 2015, , 1-5.		0
229	Fibulins. , 2015, , 1725-1729.		0
230	Systematic Validation of Breast Cancer Biomarkers Using Tissue Microarrays: From Construction to Image Analysis. , 2008, , 235-250.		0
231	Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes. Anticancer Research, 2007, 27, 1301-7.	1.1	0